Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06122779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06122779 · ClinicalTrials.gov record · last posted 2026-07-30

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Study acronym: AURORA-HFpEF
StatusActive, Not Recruiting
PhasePhase 2
Started2023-11-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

Protocol amendment history 4 changes detected by DataLookout

2026-07-31
Enrollment closed, study ongoing
2026-07-31
Trial sites reduced: 117 → 86 locations
2026-07-14
Primary completion pushed: 2026-07-03 → 2026-12-14
2026-07-14
Completion pushed: 2026-07-03 → 2026-12-14
Trial Details
NCT Number NCT06122779
Lead Sponsor Bristol-Myers Squibb
Conditions Heart Failure
Enrollment 227 participants
Start Date 2023-11-07
Primary Completion 2026-12-14 (estimated)
Study Completion 2026-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-30